NASDAQ: PMVPPmv Pharmaceuticals Inc Stock
$1.29-0.03 (-2.27%)
Updated Dec 1, 2025
PMVP Price
$1.29
Fair Value Price
$0.77
Market Cap
$68.64M
52 Week Low
$0.81
52 Week High
$1.84
P/E
-0.81x
P/B
0.57x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$82.71M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.11
Operating Cash Flow
-$73M
Beta
1.25
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
PMVP Overview
PMV Pharmaceuticals, Inc. is developing small molecule and tumor-agnostic therapies for p53 mutations in cancer. Formerly PJ Pharmaceuticals, Inc., the company was incorporated in 2013 and is headquartered in Cranbury, NJ.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PMVP's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
PMVP
Ranked#397 of 484
Ranked#397 of 484
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $6.67 | A | |
| $21.16 | A | |
| $335.60 | A |
Be the first to know about important PMVP news, forecast changes, insider trades & much more!
PMVP News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PMVP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PMVP ($1.29) is overvalued by 67.66% relative to our estimate of its Fair Value price of $0.77 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
PMVP ($1.29) is not significantly undervalued (67.66%) relative to our estimate of its Fair Value price of $0.77 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
PMVP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PMVP due diligence checks available for Premium users.
Valuation
PMVP fair value
Fair Value of PMVP stock based on Discounted Cash Flow (DCF)
Price
$1.29
Fair Value
$0.77
Overvalued by
67.66%
PMVP ($1.29) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PMVP ($1.29) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PMVP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PMVP price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.81x
Industry
209.75x
Market
45.08x
PMVP price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.57x
Industry
5.22x
PMVP is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PMVP's financial health
Profit margin
Revenue
$0.0
Net Income
-$21.1M
Profit Margin
0%
PMVP's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$133.8M
Liabilities
$12.8M
Debt to equity
0.11
PMVP's short-term assets ($132.45M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PMVP's short-term assets ($132.45M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PMVP's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
PMVP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$19.8M
Investing
$12.0M
Financing
$0.0
PMVP's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PMVP vs Biotech Stocks
Pmv Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.